Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020 Read More

Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update Read More

Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million Read More

Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer Read More

Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders Read More

Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update Read More

Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020 Read More

Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma Read More

Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million Read More

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Read More

Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma Read More

Idera Pharmaceuticals Provides 2020 Update and Outlook Read More